Regeneron - Entering the Commercial TRAP

July 2011 | 7 pages | ID: R3C91772178EN
MP Advisors

Abstracts

Eylea (VEGF Trap-Eye, R, partnered with Bayer for Ex-US) for wet age-related macular degeneration (AMD) should win approval in the US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the risk and the pipeline is included in this report. Purchase of this report will entitle the buyer to other relevant notes on REGN!!

Contents

COMPANIES MENTIONED

REGENERON